Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

A shower of awards at the DKFZ

No. 65a | 20/12/2017 | by Koh

Six young cancer researchers can look forward to receiving science awards on Tuesday, December 19, 2017. The Waltraud Lewenz Award, the Walther and Christine Richtzenhain Award, the Andreas Zimprich Award and the Nicola Werner Research Award for young scientists will be presented by the German Cancer Research Center (DKFZ) at a festive ceremony. The Bayer Foundation awards the Bayer Early Excellence in Science Award at the same occasion.

From left to right: Christoph Geisenberger (Andreas Zimprich-Award); Elham Pishali (Richtzenhain-Award); Daniel Hasche (Nicola Werner Award); Theresa Bunse (Bayer Early Excellence in Science Award); David Brocks (Waltraud-Lewenz-Award).
© Uwe Ansbach/DKFZ

The 2017 Waltraud Lewenz Award, which carries a monetary prize of €7,500, goes to David Brocks from the Epigenomics and Cancer Risk Factors Division. Brocks discovered that specific drugs that are intended to erase epigenetic alterations in tumor cells also promote the production of multiple mysterious gene transcripts. This extraordinary gene activity has the potential to stimulate the immune system – a previously unnoticed effect that can enhance the effect of the therapeutic agents.

The Waltraud Lewenz Award is named after its founder, a school teacher from Wiesbaden, Germany, who died from cancer in 1999 at the age of 58. The award is part of her bequest and is awarded biannually for outstanding research at DKFZ in the areas of "Cancer Risk Factors and Prevention" and "Diagnostics and Experimental Therapy".

The Richtzenhain Award, which this year is awarded for doctoral theses, is shared in equal halves of €2,500 by two award winners from the German Cancer Consortium (DKTK):

Susan Kläger, who currently works at the Broad Institute of MIT and Harvard in the USA, is being honored for her research at the DKTK partner site at Munich Technical University. In her PhD thesis, she was able to show that a group of targeted anticancer drugs called kinase inhibitors have a considerably broader spectrum of activity than originally expected.

Elham Pishali undertook her award-winning PhD thesis at the DKTK partner site at Dresden Technical University where she examined how T cells can be directed specifically against prostate cancer cells with the goal of developing a combined radio-immunotherapy against the disease.

The award goes back to physicians Walther and Christine Richtzenhain, a married couple from Darmstadt, Germany. Several years before her own death in 1975, Christine Richtzenhain had founded the Walther and Christine Richtzenhain Award to commemorate her husband Walther, who had died from pancreatic cancer. Richtzenhain was a neurologist and psychiatrist who had also studied theology. He was actively involved in the German Peace Society (DFG). One of the very first winners of the Richtzenhain Award in 1971 was Harald zur Hausen, who later became a Nobel Prize winner and was DKFZ Chairman of the Board for many years.

This year's Andreas Zimprich Award, which is accompanied by a monetary prize of €2,500, will be given to Christoph Geisenberger, who currently pursues research at the Hubrecht Institute for Developmental Biology and Stem Cell Research in Utrecht, Netherlands. He receives the award for his research on biomarkers that are associated with long-term survival in glioblastoma. He undertook this research at the Neurosurgery Department of Heidelberg University Hospital.

The award goes back to the Zimprich family from Heilbronn, Germany, whose son Andreas died from brain cancer a couple of years ago. The family decided at the time to support research in the area of neuro-oncology. Jointly with the DKFZ, they established the Andreas Zimprich Foundation, which has awarded the Andreas Zimprich Award for an outstanding medical doctoral thesis in neuro-oncology since 2015.

The 2017 Nicola Werner Research Award for young scientists is given to Daniel Hasche from the DKFZ Division of Viral Transformation Mechanisms. The young virus researcher has recently been the first to prove experimentally that specific types of human papillomavirus are also responsible for the development of non-melanoma skin cancer.

The €2,000 Nicola Werner Award is named after an artist who died from an HPV induced tumor. She was committed to supporting research on HPV and to making prevention possibilities such as HPV vaccination more widely known. The award is a distinction intended for young scientists at DKFZ with an outstanding doctoral thesis or publication in the area of HPV research.

This year's Bayer Early Excellence in Science Award, which carries a monetary prize of €10,000 and thus has the highest budget of the awards presented that day, is given to Theresa Bunse for her research at the Clinical Cooperation Unit "Neuroimmunology". With this award, the Bayer Foundation aims to support creative young researchers at early stages in their career.

Theresa Bunse had developed a vaccine that causes a highly specific immune response against a characteristically altered protein in many tumors. The vaccine was capable of stopping tumor growth in mice and is already being examined for safety in a phase I clinical trial.

Jointly with the award winners, the Scientific Council of the DKFZ on that day celebrates its exact 40th anniversary of commitment to research matters at the Center.

A picture is available for download:

From left to right: Christoph Geisenberger (Andreas Zimprich-Award); Elham Pishali (Richtzenhain-Award); Daniel Hasche (Nicola Werner Award); Theresa Bunse (Bayer Early Excellence in Science Award); David Brocks (Waltraud-Lewenz-Award).

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: Uwe Ansbach/DKFZ".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: Any commercial use is prohibited.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS